한국 제약기업 라이센싱-아웃 현황과 주요 특성

• 영문명: Status and Key Characteristics of Licensing-out by Korean Pharmaceutical Companies: Focusing on Licensing with Global Big Pharma
• 발행기관: 한국보건사회약료경영학회
• 저자명: 이소정 이상원
• 간행물 정보: 『한국보건사회약료경영학회지』제11권 제2호, 82~87쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2023.11.30

영문 초록

This study explored the characteristics of licensing-out deals with big pharma of Korean pharmaceutical companies participated as a licensor. Three-hundred and eighty five licensing-out deals signed between 2011 and 2022 were gathered from the Evaluate Pharma database. Logistic regression analysis indicated that large firms in Korea were about four times more likely to sign a licensing-out agreement with big pharma(p<0.05). Licensing-out deals signed between 2017 and 2022 were found to be 0.67 times less likely to sign a contract with big pharma(p<0.05) compared with between 2011 and 2016. Based on the results of this study, it suggests that Korean pharmaceutical companies should gradually advance into the global market based on profits through licensing with big pharma.

목차

서 론

연구 방법

연구 결과

고 찰

결 론

References

키워드

licensing licensing-out Korea pharmaceutical company big pharma partner